Development Agreement Sample Contracts

Lightlake Therapeutics Inc. – AESICA QUEENBOROUGH LIMITED and OPIANT PHARMACEUTICALS INC DEVELOPMENT AGREEMENT Re: Development of a Device Capable of Administering Nalmefene Hydrochloride (September 10th, 2018)
Revance Therapeutics – First Amendment to Manufacture and Development Agreement (August 3rd, 2018)

This First Amendment to the Manufacture and Development Agreement by and between Bachem Americas, Inc. (formerly American Peptide Company, Inc.) ("Bachem") located at 3132 Kashiwa Street, Torrance, CA 90505, and Revance Therapeutics, Inc. ("Revance") located at 7555 Gateway Boulevard, Newark, CA 94560, is effective as of the date of the final signature below (the "First Amendment Effective Date").

Aridis Pharmaceuticals, Inc. – Formulation Development Agreement (July 18th, 2018)

This FORMULATION DEVELOPMENT AGREEMENT (this Agreement) is entered into as of June l, 2007 (the Effective Date) by and between Aridis Pharmaceuticals, LLC, a California corporation with its business at 5941 Optical Court, San Jose, CA 95138 (Aridis) and PATH Vaccine Solutions, a nonprofit organization and affiliate of PATH organized as a separate legal entity under the laws of the State of Washington, having a primary place of business at 1455 NW Leary Way, Seattle, WA 98107 (PVS).

Zander Therapeutics, Inc – COLLABORATION AND DEVELOPMENT Agreement (July 10th, 2018)

This Collaboration Agreement ("Agreement") is made as of July 5, 2018 (the "Effective Date") by and between Ampersand Biopharmaceuticals, Inc, a Delaware corporation with offices located at 2545 W. Hillcrest Dr., Thousand Oaks, CA 91320 ("Ampersand"), and Zander Therapeutics, Inc. a Nevada corporation, with offices located at 4700 Spring Street, Suite 304 La Mesa, CA, 91942, USA ("Zander"). Ampersand and Zander are sometimes referred to in this Agreement individually as a "Party", and collectively as the "Parties".

Entest Biomedical, Inc. – COLLABORATION AND DEVELOPMENT Agreement (July 10th, 2018)

This Collaboration Agreement ("Agreement") is made as of July 5, 2018 (the "Effective Date") by and between Ampersand Biopharmaceuticals, Inc, a Delaware corporation with offices located at 2545 W. Hillcrest Dr., Thousand Oaks, CA 91320 ("Ampersand"), and Zander Therapeutics, Inc. a Nevada corporation, with offices located at 4700 Spring Street, Suite 304 La Mesa, CA, 91942, USA ("Zander"). Ampersand and Zander are sometimes referred to in this Agreement individually as a "Party", and collectively as the "Parties".

Innovative Industrial Properties Inc – Development Agreement (May 31st, 2018)

THIS DEVELOPMENT AGREEMENT is made and entered into effective this 31st day of May, 2018 (the "Effective Date"), by and between IIP-MA 1 LLC, a Delaware limited liability company ("Landlord"), PHARMACANNIS MASSACHUSETTS INC., a Massachusetts corporation ("Tenant"), and IIP OPERATING PARTNERSHIP, LP, a Delaware limited partnership ("Parent Company"). Landlord, Tenant and Parent Company shall sometimes collectively be referred to herein as the "Parties."

Fragmented Industry Exchange Inc – Outsource Technology Development Agreement (May 15th, 2018)

This Outsource Technology Development Agreement (this "Agreement") is entered into and effective as of this 1st day of March, 2018 (the "Effective Date") by and between Document Security Systems, Inc., a corporation organized and existing under the laws of the State of New York ("DSS"), and HotApp International Ltd., a corporation organized and existing under the laws of Hong Kong ("Developer").

Tapinator, Inc. – Game Engine and Game-Specific Development Agreement (April 30th, 2018)

This Game Engine and Game-Specific Development Agreement (this "Agreement") is entered into as of June 17, 2014, by and between Tapinator, Inc., a public Delaware corporation (the "Company"), and Khurram Samad ("KS").

Aridis Pharmaceuticals, Inc. – Formulation Development Agreement (April 20th, 2018)

This FORMULATION DEVELOPMENT AGREEMENT (this Agreement) is entered into as of June l, 2007 (the Effective Date) by and between Aridis Pharmaceuticals, LLC, a California corporation with its business at 5941 Optical Court, San Jose, CA 95138 (Aridis) and PATH Vaccine Solutions, a nonprofit organization and affiliate of PATH organized as a separate legal entity under the laws of the State of Washington, having a primary place of business at 1455 NW Leary Way, Seattle, WA 98107 (PVS).

Sea Ltd – AMENDED AND RESTATED MOBILE GAME DEVELOPMENT AGREEMENT (Cover Page) (April 11th, 2018)

This Amended and Restated Mobile Game Development Agreement, which consists of this Cover Page, the Terms and Conditions attached as Attachment 1 and the other Attachments listed above, each of which are incorporated by reference (collectively, the Agreement) is entered into as of the Effective Date and amended and restated as of 8 March 2018 between Tencent and Garena. This Agreement is effective as of the Effective Date and contains the terms and conditions under which Garena grants Tencent the right to make available Branded Games.

Design and Development Agreement (Step 2) (March 7th, 2018)

This Step 2 Design and Development Agreement (this "Agreement") is entered into as of, 2017 (the "Effective Date") by and between HAPSMobile Inc., a Japanese corporation having its principal place of business at 1-9-1 Higashi-Shimbashi, Minato-ku, Tokyo, Japan ("HAPSMobile") and AeroVironment, Inc., a Delaware corporation having its principal place of business at 800 Royal Oaks Drive, Suite 210, Monrovia, CA 91016, U.S.A. ("AV"). HAPSMobile and AV hereinafter will be referred to individually as "Party" and collectively as "Parties".

Marriot Vacations Worldwide Cor – First Amendment to License, Services, and Development Agreement (For Ritz- Carlton Projects) (February 27th, 2018)

This First Amendment to License, Services, and Development Agreement (this "Amendment") is executed as of February 26, 2018 by The Ritz-Carlton Hotel Company, L.L.C., a Delaware limited liability company ("Licensor"), and Marriott Vacations Worldwide Corporation, a Delaware corporation ("Licensee").

Marriot Vacations Worldwide Cor – First Amendment to License, Services, and Development Agreement (For Marriott Projects) (February 27th, 2018)

This First Amendment to License, Services, and Development Agreement (this "Amendment") is executed as of February 26, 2018 by Marriott International, Inc., a Delaware corporation ("MII"), and Marriott Worldwide Corporation, a Maryland corporation ("MWC") (MII and MWC are referred to collectively herein as "Licensor"), and Marriott Vacations Worldwide Corporation, a Delaware corporation ("Licensee").

First Amendment to License, Services, and Development Agreement (For Ritz- Carlton Projects) (February 27th, 2018)

This First Amendment to License, Services, and Development Agreement (this "Amendment") is executed as of February 26, 2018 by The Ritz-Carlton Hotel Company, L.L.C., a Delaware limited liability company ("Licensor"), and Marriott Vacations Worldwide Corporation, a Delaware corporation ("Licensee").

First Amendment to License, Services, and Development Agreement (February 27th, 2018)

This First Amendment to License, Services, and Development Agreement (this "Amendment") is executed as of February 26, 2018 by Marriott International, Inc., a Delaware corporation ("MII"), and Marriott Worldwide Corporation, a Maryland corporation ("MWC") (MII and MWC are referred to collectively herein as "Licensor"), and Marriott Vacations Worldwide Corporation, a Delaware corporation ("Licensee").

STERLING CONSOLIDATED Corp – Token Development Agreement (February 2nd, 2018)

This Token Development Agreement ("Agreement") is made as of January 29, 2018, by and between UPGRADE DIGITAL INC. d/b/a BlockchainDriven, a New York corporation with an address at 33 W. 19th Street, New York, NY 10001 ("Developer") and STERLING CONSOLIDATED CORP., a Nevada corporation with an address at 1105 Green Grove Road, Neptune City, NJ 07753 ("STCC")

Tfi Tab Gida Yatirimlari A.S. – AMENDED AND RESTATED DEVELOPMENT AGREEMENT Dated 5 June 2002 as Previously Amended by the First Amendment on 27 May 2013 and as Amended and Restated on 22 January 2018 Among (January 22nd, 2018)

THIS AMENDED AND RESTATED DEVELOPMENT AGREEMENT (this Agreement) dated 5 June 2002 as previously amended by the First Amendment on 27 May 2013 and as amended and restated on 22 January 2018 with effect from the Effective Date (defined below), is made and delivered as a deed among:

Tfi Tab Gida Yatirimlari A.S. – Master Franchise and Development Agreement (January 18th, 2018)
Isoray – Collaborative Development Agreement (January 8th, 2018)

This Collaborative Development Agreement (the "Agreement"), effective as of March 13, 2017, (the "Effective Date"), is made by and between IsoRay Medical, Inc., a Delaware corporation with offices at 350 Hills St., Suite 106, Richland, WA 99354 ("IsoRay"), and GammaTile, LLC, an Arizona limited liability company, having its principal place of business at 2242 E. Catclaw St Gilbert, AZ 85296 ("GammaTile LLC"). IsoRay and GammaTile LLC may be referred to herein individually as a "Party", and collectively as the "Parties".

Tfi Tab Gida Yatirimlari A.S. – Master Franchise and Development Agreement (December 29th, 2017)
InfraREIT, Inc. – FIRST AMENDMENT to Development Agreement November 9, 2017 (November 16th, 2017)

This First Amendment (this First Amendment) to the Development Agreement by and among Hunt Transmission Services, L.L.C. (Hunt), Sharyland Utilities, L.P. (Sharyland), InfraREIT Partners, LP (the Operating Partnership), InfraREIT, Inc. (the REIT and, together with the Operating Partnership and all direct and indirect subsidiaries of the REIT, InfraREIT) is effective as of November 9, 2017. Hunt, Sharyland, the Operating Partnership and the REIT are sometimes referred to in this First Amendment individually as a Party or collectively as the Parties. Capitalized terms used herein that are not otherwise defined will have the meanings assigned to such terms in the Development Agreement (as defined below).

Third Amendment to the Product Supply and Development Agreement (November 6th, 2017)

DEVELOPMENT AGREEMENT ("Amendment"), effective as of September 15, 2017 (the "Effective Date"), is by and between EaglePicher Medical Power LLC ("EPMP LLC"), a Delaware Corporation having an address of "C"and Porter Streets, Joplin, MO 64801 and Nevro Corp. ("Buyer"), a Delaware Corporation, having its principal place of business at 1800 Bridge Parkway, Redwood City, CA 94065 .

Development Agreement (October 26th, 2017)

This Development Agreement (this "Agreement") is made and entered into on June 4, 2015 (the "Effective Date") by and between Tandem Diabetes Care, Inc., a Delaware corporation, having a principal place of business at 11045 Roselle St., San Diego, CA 92121 ("Tandem") and DexCom, Inc., a Delaware corporation, having a principal place of business at 6340 Sequence Drive, San Diego, CA 92121 ("DexCom").

Fireman B.V. – Co-Development Agreement (October 13th, 2017)

efforts of the Parties and set the rules and conditions for such co-development as in principle set forth above (hereinafter also referred to as the "Purpose" of this Agreement).

Aptevo Therapeutics Inc. – Fourth Amendment to License and Co-Development Agreement (August 10th, 2017)

THIS FOURTH AMENDMENT ("Fourth Amendment") effective as of June 19, 2017 ("Effective Date"), is made by and between MorphoSys AG, a German corporation (registered at the District Court of Munich, HRB121023) having an office and place of business at Semmelweisstrasse 7, 82152Planegg, Germany, (collectively with its affiliates, "Morphosys") and Aptevo Research and Development LLC (previously Emergent Product Development Seattle, LLC), a US corporation (registered in Delaware, Ndeg 4858233) having an office and place of business at 2401 Fourth Avenue, Suite 1050, Seattle, Washington, USA ("Aptevo").

Fireman B.V. – Co-Development Agreement (August 3rd, 2017)

efforts of the Parties and set the rules and conditions for such co-development as in principle set forth above (hereinafter also referred to as the "Purpose" of this Agreement).

Edge Therapeutics, Inc. – Amended and Restated Master Formulation Development Agreement (August 1st, 2017)

This Amended and Restated Master Formulation Development Agreement (the "Agreement"), dated June 30, 2017 (the "Amendment and Restatement Effective Date"), is made by and between Oakwood Laboratories, L.L.C., a Delaware limited liability company having an address of 7670 First Place, Suite A, Oakwood Village, OH 44146 ("Oakwood"), and Edge Therapeutics, Inc., a New Jersey corporation having an address of 300 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922 ("Edge"). Edge and Oakwood are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

Vitro Diagnostics – Stem Cell Lab Development Agreement (July 11th, 2017)

This STEM CELL LAB DEVELOPMENT AGREEMENT (this "Agreement") made the 6th day of July, 2017 , by and between DaVinci Centre for Wellness and Alternative Therapies, formed and organized under the laws of the Cayman Islands ("DaVinci"), Halo Cell Sciences, Ltd, a Cayman Islands corporation ("Cell Sciences"), and Vitro Diagnostics, Inc., a Nevada corporation ("Vitro"). DaVinci, Cell Sciences, and Vitro are sometimes referred to herein collectively as the "Parties " and each individually as a "Party." This signed Stem Cell Development Agreement shall become effective upon the minimum sufficient funding in the amount of $1,500,000 being raised by Vitro and the completion of the items detailed in the "Terms of Agreement" laid out below.

Litorium Group Corp. – Web Site Development Agreement (June 30th, 2017)

THIS AGREEMENT is made and entered into as of this April 4, 2017 (the Effective Date) by and between TANA MA SOFTWARE, LLC (THE COMPANY) and LITORIUM GROUP CORP. (THE DEVELOPER).

Litorium Group Corp. – Web Site Development Agreement (June 30th, 2017)

THIS AGREEMENT is made and entered into as of this March 2, 2017 (the Effective Date) by and between PAVERS MICRO, LLC (THE COMPANY) and LITORIUM GROUP CORP. (THE DEVELOPER).

Nuvectra Corp – Second Amendment to the Development Agreement (June 21st, 2017)

This Second Amendment (the "Amendment No. 2") dated as of June 19, 2017 (the "Amendment Effective Date") to the Development Agreement, is by and between Nuvectra Corporation (f/k/a QIG Group, LLC), located at 5830 Granite Parkway, Suite 1100, Plano, TX 75223 ("Nuvectra"), and Aleva Neurotherapeutics S.A., located at EPFL Innovation Park, Building D, 1015 Lausanne, Switzerland ("Aleva").

Flexsteel Industries, Inc. – Development Agreement (June 12th, 2017)

THIS DEVELOPMENT AGREEMENT (this Agreement), dated for reference purposes the 5th_ day of _June___, 2017, between the City of Dubuque, Iowa, a municipality (City), established pursuant to the Iowa Code and acting under authorization of Iowa Code Chapter 403, as amended (Urban Renewal Act), and Flexsteel Industries, Inc., an Iowa corporation, with its principal place of business in Dubuque, Iowa (Developer).

Co-Development Agreement (May 30th, 2017)

American BriVision Corporation, a company incorporated under the laws of USA and having it principle place of business at 11 Sawyers Peak Drive, Goshen, NY 10924 USA ("ABVC")

Five Point Holdings, LLC – DISPOSITION AND DEVELOPMENT AGREEMENT (CANDLESTICK POINT AND PHASE 2 OF THE HUNTERS POINT SHIPYARD) by and Between REDEVELOPMENT AGENCY OF THE CITY AND COUNTY OF SAN FRANCISCO, a Public Body, Corporate and Politic, of the State of California and CP DEVELOPMENT CO., LP, a Delaware Limited Partnership (April 7th, 2017)

This DISPOSITION AND DEVELOPMENT AGREEMENT (CANDLESTICK POINT AND PHASE 2 OF THE HUNTERS POINT SHIPYARD) (including all Exhibits and as amended from time to time, this DDA) dated for reference purposes only as of June 3, 2010 (the Reference Date), is made by and between Developer and the Agency. The terms defined in Exhibit B that are used in this DDA have the meanings given to them in Exhibit B.

Five Point Holdings, LLC – Recorders Stamp SECOND AMENDMENT TO DISPOSITION AND DEVELOPMENT AGREEMENT (Candlestick Point and Phase 2 of the Hunters Point Shipyard) (April 7th, 2017)

This SECOND AMENDMENT TO DISPOSITION AND DEVELOPMENT AGREEMENT (CANDLESTICK POINT AND PHASE 2 OF THE HUNTERS POINT SHIPYARD) (this Second Amendment), dated as of December 1, 2014 (the Second Amendment Reference Date), is entered into by and between the SUCCESSOR AGENCY TO THE REDEVELOPMENT AGENCY OF THE CITY AND COUNTY OF SAN FRANCISCO, a public body, organized and existing under the laws of the State of California (the Agency), and CP DEVELOPMENT CO., LP, a Delaware limited partnership (Developer), with reference to the following facts and circumstances: